Literature DB >> 24021477

Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Eugenia Trushina1, Christie A Canaria, Do-Yup Lee, Cynthia T McMurray.   

Abstract

Loss of cholesterol homeostasis and altered vesicle trafficking have been detected in Huntington's disease (HD) cellular and animal models, yet the role of these dysfunctions in pathophysiology of HD is unknown. We demonstrate here that defects in caveolar-related cholesterol trafficking directly contribute to the mechanism of HD in vivo. We generated new mouse models that express mutant Huntington's protein (mhtt), but have partial or total loss of caveolin-1 (Cav1) expression. Fluorescence resonance energy transfer dequenching confirms a direct interaction between mhtt and Cav1. Mhtt-expressing neurons exhibited cholesterol accumulation and suppressed caveolar-related post-Golgi trafficking from endoplasmic reticulum/Golgi to plasma membrane. Loss or reduction of Cav1 expression in a knock-in HD mouse model rescues the cholesterol phenotype in neurons and significantly delays the onset of motor decline and development of neuronal inclusions. We propose that aberrant interaction between Cav1 and mhtt leads to altered cholesterol homeostasis and plays a direct causative role in the onset of HD pathophysiology in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24021477      PMCID: PMC3857950          DOI: 10.1093/hmg/ddt406

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  59 in total

Review 1.  Cholesterol involvement in the pathogenesis of neurodegenerative diseases.

Authors:  Jun-Ping Liu; Ying Tang; Shufeng Zhou; Ban Hock Toh; Catriona McLean; He Li
Journal:  Mol Cell Neurosci       Date:  2009-08-04       Impact factor: 4.314

2.  Combined haematoxylin, eosin and fluorescent stain for paraffin sections.

Authors:  P Trenchev; M Konopka
Journal:  Pathology       Date:  1980-01       Impact factor: 5.306

3.  Huntington disease phenocopy is a familial prion disease.

Authors:  R C Moore; F Xiang; J Monaghan; D Han; Z Zhang; L Edström; M Anvret; S B Prusiner
Journal:  Am J Hum Genet       Date:  2001-10-09       Impact factor: 11.025

4.  The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.

Authors:  Ben Woodman; Rachel Butler; Christian Landles; Michelle K Lupton; Jamie Tse; Emma Hockly; Hilary Moffitt; Kirupa Sathasivam; Gillian P Bates
Journal:  Brain Res Bull       Date:  2006-12-05       Impact factor: 4.077

5.  Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease.

Authors:  Daniel del Toro; Xavier Xifró; Albert Pol; Sandrine Humbert; Frédéric Saudou; Josep M Canals; Jordi Alberch
Journal:  J Neurochem       Date:  2010-08-12       Impact factor: 5.372

6.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

7.  Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface.

Authors:  Cristina Guardia-Laguarta; Mireia Coma; Marta Pera; Jordi Clarimón; Lidia Sereno; José M Agulló; Laura Molina-Porcel; Eduard Gallardo; Amy Deng; Oksana Berezovska; Bradley T Hyman; Rafael Blesa; Teresa Gómez-Isla; Alberto Lleó
Journal:  J Neurochem       Date:  2009-04-27       Impact factor: 5.372

Review 8.  Lysosomal disorders: from storage to cellular damage.

Authors:  Andrea Ballabio; Volkmar Gieselmann
Journal:  Biochim Biophys Acta       Date:  2008-12-08

9.  Caveolin targeting to late endosome/lysosomal membranes is induced by perturbations of lysosomal pH and cholesterol content.

Authors:  Dorothy I Mundy; Wei Ping Li; Katherine Luby-Phelps; Richard G W Anderson
Journal:  Mol Biol Cell       Date:  2012-01-11       Impact factor: 4.138

10.  Caveolae, caveolins, cavins, and endothelial cell function: new insights.

Authors:  Grzegorz Sowa
Journal:  Front Physiol       Date:  2012-01-06       Impact factor: 4.566

View more
  14 in total

1.  Oxidative metabolism in YAC128 mouse model of Huntington's disease.

Authors:  James Hamilton; Jessica J Pellman; Tatiana Brustovetsky; Robert A Harris; Nickolay Brustovetsky
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

2.  Mutant huntingtin fails to directly impair brain mitochondria.

Authors:  James Hamilton; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  J Neurochem       Date:  2019-10-07       Impact factor: 5.372

3.  Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease.

Authors:  James Hamilton; Jessica J Pellman; Tatiana Brustovetsky; Robert A Harris; Nickolay Brustovetsky
Journal:  Hum Mol Genet       Date:  2016-04-30       Impact factor: 6.150

4.  Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease.

Authors:  Seon-Heui Cha; Yu Ree Choi; Cheol-Ho Heo; Seo-Jun Kang; Eun-Hye Joe; Ilo Jou; Hwan-Myung Kim; Sang Myun Park
Journal:  Mol Neurodegener       Date:  2015-12-01       Impact factor: 14.195

5.  CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.

Authors:  Lydie Boussicault; Sandro Alves; Antonin Lamazière; Anabelle Planques; Nicolas Heck; Lara Moumné; Gaëtan Despres; Susanne Bolte; Amélie Hu; Christiane Pagès; Laurie Galvan; Francoise Piguet; Patrick Aubourg; Nathalie Cartier; Jocelyne Caboche; Sandrine Betuing
Journal:  Brain       Date:  2016-01-29       Impact factor: 13.501

6.  Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease.

Authors:  Helen Budworth; Faye R Harris; Paul Williams; Do Yup Lee; Amy Holt; Jens Pahnke; Bartosz Szczesny; Karina Acevedo-Torres; Sylvette Ayala-Peña; Cynthia T McMurray
Journal:  PLoS Genet       Date:  2015-08-06       Impact factor: 5.917

7.  Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.

Authors:  A M Petrov; M R Kasimov; A L Zefirov
Journal:  Acta Naturae       Date:  2016 Jan-Mar       Impact factor: 1.845

8.  Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.

Authors:  Marta Valenza; Jane Y Chen; Eleonora Di Paolo; Barbara Ruozi; Daniela Belletti; Costanza Ferrari Bardile; Valerio Leoni; Claudio Caccia; Elisa Brilli; Stefano Di Donato; Marina M Boido; Alessandro Vercelli; Maria A Vandelli; Flavio Forni; Carlos Cepeda; Michael S Levine; Giovanni Tosi; Elena Cattaneo
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

9.  Alteration in Fluidity of Cell Plasma Membrane in Huntington Disease Revealed by Spectral Phasor Analysis.

Authors:  Sara Sameni; Leonel Malacrida; Zhiqun Tan; Michelle A Digman
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

10.  XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.

Authors:  Aris A Polyzos; Nigel I Wood; Paul Williams; Peter Wipf; A Jennifer Morton; Cynthia T McMurray
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.